(Reuters) - The inquiry also covers Dendreon's marketing application for Provenge, the U.S. Food and Drug Administration's review of the vaccine and related correspondence to and from the company from Jan. 1, the company said in a filing on Tuesday. In May, the biotechnology company said the FDA issued an "approvable letter" for Provenge but wanted additional clinical data and more information about chemistry, manufacturing and controls.
The company said it intends to fully cooperate with the SEC.
Read more at Reuters.com Government Filings News
The company said it intends to fully cooperate with the SEC.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment